Resistin is a novel peptide specifically secreted from adipocytes, and implicated in insulin resistance. We 
Introduction
Adipose tissue has recently been considered to play not only a role in lipid metabolism, but also active endocrine roles in secreting a variety of bioactive molecules, such as leptin (1) , adiponectin (2) , tumor necrosis factor-α (TNF-α) (3) , and resistin (4) . Resistin is a recently discovered peptide hormone specifically secreted by adipose tissue, and has been suggested to be involved in the pathogenesis of insulin resistance, which may link obesity with diabetes (4) . Adrenomedullin (AM) is a potent vasodilator peptide consisting of 52 amino acids, and was originally isolated from human pheochromocytoma (5) . AM also plays many other physiological roles, including regulation of renal function (6) , neurotransmission (7), cell proliferation (8, 9) and suppressive actions on insulin secretion (10, 11) . AM is ubiquitously expressed in many types of cells (12) 
Cell Culture and Differentiation
3T3-L1 cells were cultivated in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS). Confluent cells were induced to differentiate to adipocytes by culturing in DMEM containing 10% FBS, 1 µg/ml insulin, 1 µmol/l dexamethasone and 0.5 mmol/l 3-isobutyl-1-methylxanthine for 48 h. The cells were then cultured in DMEM containing 10% FBS, as shown in Fig. 1A . 3T3-L1 cells cultured in medium without insulin, dexamethasone or 3-isobutyl-1-methylxanthine were used as preadipocytes. The cells were harvested for RNA extraction and the cultured media were collected for the measurement of immunoreactive adrenomedullin (IR-AM). The experiments were performed in five dishes per each treatment.
RNA Extraction and Northern Blot Analysis
Total cellular RNA was isolated from 3T3-L1 cells using TRIZOL reagent (Life Technologies, Gaithersburg, USA) according to the manufacturer's instructions. Northern blot analysis was performed as previously reported (19) .
Northern probes for AM and resistin were prepared by reverse transcriptase-polymerase chain reaction (RT-PCR) using total RNA prepared from rat adrenal glands (for AM) and 3T3-L1 adipocytes (for resistin). The sense primer for rat AM was 5 -TTCGAGTCAAACGCTACCGC-3 . (nucleotides 266-285) and the anti-sense primer was 5 -ATCAGGCGCTCTCCACCTTA-3 (complementary to nucleotides 1102-1121) (20) . The sense primer for resistin was 5 -TTGTGTCCTGCTAAGTCCTC-3 (nucleotides 47-66) and the antisense primer was 5 -ACATCAGGAAGCGACC TGCA-3 (complementary to nucleotides 412-431) (Gene Bank accession No. AF323080). The amplified cDNA fragments were inserted into the EcoRV site of the pBluescript I KS vector (Stratagene, La Jolla, USA), yielding the subclones pBS-rAM10 and pBS-mRes, respectively. The nucleotide sequences were determined using an autosequencer (Perkin-Elmer, Chiba, Japan) and were confirmed to be identical to the registered sequences of rat AM (20) and mouse resistin (Gene Bank accession No. AF323080). The HindIII/NaeI fragment of pBS-rAM10 (vector/443) and the HindIII/EcoRI fragment of pBS-mRes (vector/vector) were labeled with [α-32 P]dCTP using a BcaBest Labeling Kit (Takara Biomedicals, Shiga, Japan). Radioactive signals were detected by exposing the filters to X-ray film (X-AR5; Eastman Kodak, Rochester, USA) or by means of a Bioimage Analyzer (BAS1500; Fujifilm, Tokyo, Japan). The radioactivity corresponding to each band was determined using a Bioimage Analyzer.
Peptide Extraction and Radioimmunoassay
Peptides in culture media were extracted using Sep-Pak C18 cartridges (Waters, Milford, USA) as previously reported (19) . The extract was reconstituted in assay buffer [0.1 mol/l phosphate buffer (pH 7.5) containing 0.1% (w/v) bovine serum albumin, 0.2% (v/v) Triton X-100 and 0.1% (w/v) sodium azide] and assayed.
Radioimmunoassay was performed using mouse AM as a standard and 125 I-human AM prepared by the chloramine T method as a radioligand (21) . The antiserum (No. 103) (16) against human AM, which cross-reacted with mouse AM, was used at a final dilution of 1:20,000. Intraassay and interassay coefficients of variation were 5.6% and 5.8%, respectively. The assay could detect changes of 10 3.4 fmol/tube (mean SD, n 5) from baseline with 95% confidence. There was no significant cross reaction ( 0.01%) with other peptides, including calcitonin gene-related peptide (CGRP).
Statistics
Data were expressed as the mean SEM, unless otherwise stated. Statistical analysis was performed by one-way analysis of variance followed by Fisher's protected least significant difference test.
Results

IR-AM Levels in the Medium of 3T3-L1 Cells
Microscopical examinations confirmed that 3T3-L1 cells showed morphological properties of adipocytes, such as accumulation of fat droplets, after the treatment with insulin, dexamethasone and 3-isobutyl-1-methylxanthine. Such changes were not observed in control preadipocytes.
IR-AM was detected in the media of both preadipocytes and adipocytes (Fig. 1B) . IR-AM concentrations were about 3 times higher in the media of preadipocytes than in those of adipocytes. On the other hand, IR-AM was not detected in the unconditioned medium (less than 25 pmol/l), whereas it was detected in the media of adipocytes (48-72 h, 77.4 6.9 fmol/10 5 cells/24 h 291.7 25.9 pmol/l; and 72-96 h, 96.2 7.8 fmol/10 5 cells/24 h 312.6 25.5 pmol/l), indicating the active secretion of IR-AM even from 3T3-L1 adipocytes.
Expression of AM and Resistin mRNAs in 3T3-L1 Cells
Northern blot analysis showed that AM mRNA was expressed in 3T3-L1 preadipocytes, but was undetectable in 3T3-L1 adipocytes (Fig. 2) . In contrast, resistin mRNA was only detected in differentiated adipocytes by Northern blot analysis. The expression levels of resistin mRNA peaked at 72 h of culture and remained high until 96 h.
Discussion
The present study has shown for the first time that AM expression was decreased during adipocyte-differentiation of 3T3-L1 cells. The low expression of AM in adipose tissue may be related to the higher incidence of hypertension in obese subjects. This finding is in marked contrast to the previous findings of increased AM expression during differentiation of THP-1 monocytic leukemia cells to macrophagelike cells (22, 23) . On the other hand, resistin mRNA was detected only in 3T3-L1 adipocytes, consistent with the previous report by Steppan et al. (4) . AM mRNA expression was undetectable in 3T3-L1 adipocytes, whereas IR-AM was detected in the culture medium of 3T3-L1 adipocytes at significantly higher levels than in unconditioned medium. This may have been due to the higher sensitivity of the radioimmunoassay and/or the higher stability of the secreted AM.
It is noteworthy, however, that differentiated adipocytes still had the ability to secrete AM in the present study. Reverse phase high performance liquid chromatography confirmed that IR-AM in the medium of 3T3 adipocytes was eluted mainly in two positions: one corresponding to mouse AM and one to mouse AM with oxidized methionine (data not shown). Hayashi et al. reported that plasma levels of AM were elevated in patients with diabetes mellitus (24) . Since many cases of diabetes are associated with obesity, and adipocytes occupy a considerable portion of the body, our findings raise the possibility that AM in the blood of diabetic patients is partly derived from adipose tissue. Another possible role of adipocyte-derived AM may be exerting autocrine and/or paracrine actions on adipocytes. The complex of calcitonin receptor-like receptor (CRLR) and receptor activity-modifying protein (RAMP)-2 or -3 generates AM receptor, whereas the complex of CRLR and RAMP-1 generates CGRP receptor (25) . It was reported that all three isoforms of RAMPs, RAMP-1, -2, and -3, are expressed in adipose tissue (26) . The β3-adrenergic receptor, predominantly expressed in adipocytes, mediates the catecholamine action on lipolysis, and there are cAMP-response elements in the promoter of the β3-adrenergic receptor gene (27, 28) . It is therefore tempting to speculate that AM may modulate the expression of β3-adrenergic receptors via the cAMP pathway as an autocrine and/or paracrine factor, and this matter will require further investigation.
AM appears to be involved in the pathophysiology of various diseases, including cardiovascular, neoplastic and inflammatory diseases (12) , and to be beneficial for the treatment of some diseases, including hypertension (29) . The present study has raised the possibility that AM is also related to the lipid metabolism and the pathophysiology of obesity and obesity-related diseases. 
